NASDAQ:NTRA - Natera Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$22.64 -1.00 (-4.23 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$22.64
Today's Range$21.15 - $22.67
52-Week Range$7.78 - $23.98
Volume865,748 shs
Average Volume967,660 shs
Market Capitalization$1.29 billion
P/E Ratio-9.43
Dividend YieldN/A
Beta2
Natera logoNatera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Debt-to-Equity Ratio-18.90
Current Ratio1.80
Quick Ratio1.68

Price-To-Earnings

Trailing P/E Ratio-9.43
Forward P/E Ratio-11.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$210.94 million
Price / Sales5.85
Cash FlowN/A
Price / CashN/A
Book Value($0.19) per share
Price / Book-119.16

Profitability

EPS (Most Recent Fiscal Year)($2.40)
Net Income$-136,310,000.00
Net Margins-58.84%
Return on Equity-752.93%
Return on Assets-66.23%

Miscellaneous

Employees893
Outstanding Shares54,510,000
Market Cap$1,288.68

Natera (NASDAQ:NTRA) Frequently Asked Questions

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) posted its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01. The medical research company earned $62.34 million during the quarter, compared to analysts' expectations of $54.86 million. Natera had a negative return on equity of 752.93% and a negative net margin of 58.84%. Natera's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.70) EPS. View Natera's Earnings History.

What price target have analysts set for NTRA?

6 Wall Street analysts have issued 12 month target prices for Natera's shares. Their forecasts range from $12.00 to $23.00. On average, they anticipate Natera's share price to reach $19.3333 in the next twelve months. This suggests that the stock has a possible downside of 14.6%. View Analyst Ratings for Natera.

What is the consensus analysts' recommendation for Natera?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Natera's key competitors?

Who are Natera's key executives?

Natera's management team includes the folowing people:
  • Dr. Matthew Rabinowitz, Co-Founder, CEO, Pres & Chairman (Age 45)
  • Mr. Michael Brophy, Chief Financial Officer (Age 38)
  • Mr. Steve Chapman, Chief Operating Officer (Age 39)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 45)
  • Mr. Daniel Rabinowitz L.L.M., LL.M., Corp. Sec. & Gen. Counsel

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Has Natera been receiving favorable news coverage?

News headlines about NTRA stock have been trending somewhat positive on Saturday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Natera earned a news impact score of 0.04 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.93 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Natera's major shareholders?

Natera's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fred Alger Management Inc. (3.24%) and Essex Investment Management Co. LLC (0.32%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

Which institutional investors are buying Natera stock?

NTRA stock was bought by a variety of institutional investors in the last quarter, including Fred Alger Management Inc. and Essex Investment Management Co. LLC. View Insider Buying and Selling for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $22.64.

How big of a company is Natera?

Natera has a market capitalization of $1.29 billion and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.


MarketBeat Community Rating for Natera (NASDAQ NTRA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.